These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 21937740)

  • 1. Evaluation of direct and indirect effects of the PPARγ agonist troglitazone on mouse endothelial cell proliferation.
    Kakiuchi-Kiyota S; Arnold LL; Yokohira M; Koza-Taylor P; Suzuki S; Varney M; Pennington KL; Cohen SM
    Toxicol Pathol; 2011 Dec; 39(7):1032-45. PubMed ID: 21937740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of PPARγ agonists on rodent endothelial cell proliferation.
    Kakiuchi-Kiyota S; Arnold LL; Yokohira M; Suzuki S; Pennington KL; Cohen SM
    Toxicology; 2011 Sep; 287(1-3):91-8. PubMed ID: 21684317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the PPARgamma agonist troglitazone on endothelial cells in vivo and in vitro: differences between human and mouse.
    Kakiuchi-Kiyota S; Vetro JA; Suzuki S; Varney ML; Han HY; Nascimento M; Pennington KL; Arnold LL; Singh RK; Cohen SM
    Toxicol Appl Pharmacol; 2009 May; 237(1):83-90. PubMed ID: 19285096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of endothelial cell proliferation in normal liver and adipose tissue in B6C3F1 mice, F344 rats, and humans.
    Ohnishi T; Arnold LL; Clark NM; Wisecarver JL; Cohen SM
    Toxicol Pathol; 2007 Dec; 35(7):904-9. PubMed ID: 18098037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
    Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
    Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor γ agonist troglitazone inhibits high mobility group box 1 expression in endothelial cells via suppressing transcriptional activity of nuclear factor κB and activator protein 1.
    Gao M; Hu Z; Zheng Y; Zeng Y; Shen X; Zhong D; He F
    Shock; 2011 Sep; 36(3):228-34. PubMed ID: 21617575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
    Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
    Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes.
    Rogue A; Renaud MP; Claude N; Guillouzo A; Spire C
    Toxicol Appl Pharmacol; 2011 Jul; 254(1):18-31. PubMed ID: 21515302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J; Morales M; Caelles C
    Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
    Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
    Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones inhibit insulin-like growth factor-i-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity.
    He G; Sung YM; Digiovanni J; Fischer SM
    Cancer Res; 2006 Feb; 66(3):1873-8. PubMed ID: 16452250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of PPARgamma ligands on UV- or chemically-induced carcinogenesis in mouse skin.
    He G; Muga S; Thuillier P; Lubet RA; Fischer SM
    Mol Carcinog; 2005 Aug; 43(4):198-206. PubMed ID: 15864802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
    Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
    Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPARγ activation induces acute PAI-1 gene expression in the liver but not in adipose tissues of diabetic model mice.
    Oishi K; Tomita T; Itoh N; Ohkura N
    Thromb Res; 2011 Nov; 128(5):e81-5. PubMed ID: 21757225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model.
    Wang K; Zhou Z; Zhang M; Fan L; Forudi F; Zhou X; Qu W; Lincoff AM; Schmidt AM; Topol EJ; Penn MS
    J Pharmacol Exp Ther; 2006 Apr; 317(1):37-43. PubMed ID: 16368901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Troglitazone inhibits endothelial cell proliferation through suppression of casein kinase 2 activity.
    Lee KS; Park JH; Lee S; Lim HJ; Jang Y; Park HY
    Biochem Biophys Res Commun; 2006 Jul; 346(1):83-8. PubMed ID: 16759638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.
    Berthiaume M; Laplante M; Tchernof A; Deshaies Y
    Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation.
    Yang CC; Wang YC; Wei S; Lin LF; Chen CS; Lee CC; Lin CC; Chen CS
    Cancer Res; 2007 Apr; 67(7):3229-38. PubMed ID: 17409431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies.
    Lindblom P; Berg AL; Zhang H; Westerberg R; Tugwood J; Lundgren H; Marcusson-Ståhl M; Sjögren N; Blomgren B; Öhman P; Skånberg I; Evans J; Hellmold H
    Toxicol Pathol; 2012; 40(1):18-32. PubMed ID: 22131108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
    Colin C; Salamone S; Grillier-Vuissoz I; Boisbrun M; Kuntz S; Lecomte J; Chapleur Y; Flament S
    Breast Cancer Res Treat; 2010 Nov; 124(1):101-10. PubMed ID: 20054646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.